PHARMACEUTICAL 2024

Alnylam Pharmaceuticals INC
Rank 205 of 309



RealRate

PHARMACEUTICAL 2024

Alnylam Pharmaceuticals INC
Rank 205 of 309

Alnylam@20

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 8.1% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 73% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	2,982,697
Cost of Goods Sold	268,216
Intangible Assets	0
Liabilities, Current	967,786
Liabilities, Non-Current	739,714
Other Assets	321,126
Other Compr. Net Income	21,279
Other Expenses	48,915
Other Liabilities	2,343,024
Other Net Income	-151,342
Other Revenues	1,828,292
Property and Equipment	526,057
Research and Development	1,004,415
Selling, General and Administrative Expense	795,646

Output Variable	Value in 1000 USD
Assets	3,829,880
Liabilities	4,050,524
Expenses	2,117,192
Revenues	1,828,292
Stockholders Equity	-220,644
Net Income	-440,242
Comprehensive Net Income	-429,602
BaseVar	5,999,254
ECR before LimitedLiability	-23%
Economic Capital Ratio	140%